Tg Therapeutics Stock Investor Sentiment

TGTX Stock  USD 30.09  1.56  5.47%   
Slightly above 70 percent of all TG Therapeutics' investors are curious in acquiring. The analysis of the overall investor sentiment regarding TG Therapeutics suggests that a large number of traders are confidant. TG Therapeutics' investing sentiment can be driven by a variety of factors including economic data, TG Therapeutics' earnings reports, geopolitical events, and overall market trends.

Comfort Level 70

 Interested

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use TG Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward TG Therapeutics.

TGTX Historical Sentiment

Although TG Therapeutics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding TGTX, such as negative comments on social media and news outlets, may cause fear in the market and push TG Therapeutics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of TGTX.
  

TG Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards TG Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

TG Therapeutics Historical Investor Sentiment

Investor biases related to TG Therapeutics' public news can be used to forecast risks associated with an investment in TGTX. The trend in average sentiment can be used to explain how an investor holding TGTX can time the market purely based on public headlines and social activities around TG Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
TG Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for TG Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average TG Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on TG Therapeutics.

TG Therapeutics Maximum Pain Price Across May 16th 2025 Option Contracts

TG Therapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of TG Therapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of TG Therapeutics' options.
a day ago at seekingalpha.com         
TG Therapeutics Q4 2024 Earnings Preview
seekingalpha News
2 days ago at gurufocus.com         
TG Therapeutics Announces Presentation of Data for BRIUMVI in M
Gurufocus Stories at Macroaxis
2 days ago at gurufocus.com         
TG Therapeutics Inc Presents Promising Data on BRIUMVI for Multiple Sclerosis
Gurufocus Stories at Macroaxis
3 days ago at finance.yahoo.com         
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2024 Financial Results and B...
Yahoo News
3 days ago at gurufocus.com         
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2024 Financial Results ...
Gurufocus Stories at Macroaxis
3 days ago at gurufocus.com         
TG Therapeutics Inc Announces Upcoming Conference Call to Discuss 2024 Financial Results
Gurufocus Stories at Macroaxis
few days ago at finance.yahoo.com         
Institutional investors in TG Therapeutics, Inc. see US243m decrease in market cap last week, althou...
Yahoo News
few days ago at www.macroaxis.com         
Acquisition by Weiss Michael S of 100000 shares of TG Therapeutics at 10.13 subject to Rule 16b-3
Macroaxis News
over a week ago at gurufocus.com         
TG Therapeutics Inc Announces Key Presentations on BRIUMVI at ACTRIMS Forum 2025
Gurufocus Stories at Macroaxis
over a week ago at zacks.com         
Novavax to Report Q4 Earnings Heres What You Can Expect
zacks News
over a week ago at globenewswire.com         
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI in Multiple Sclerosis at the Am...
Macroaxis News: globenewswire.com
over a week ago at gurufocus.com         
TG Therapeutics Announces Schedule of Data Presentations for BRI
Gurufocus Stories at Macroaxis
over a week ago at finance.yahoo.com         
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI in Multiple Sclerosis at the Am...
Yahoo News
over a week ago at finance.yahoo.com         
BioMarin to Report Q4 Earnings Heres What to Expect
Yahoo News
over a week ago at thelincolnianonline.com         
Legato Capital Management LLC Sells 3,104 Shares of TG Therapeutics, Inc.
news
Far too much social signal, news, headlines, and media speculation about TG Therapeutics that are available to investors today. That information is available publicly through TGTX media outlets and privately through word of mouth or via TGTX internal channels. However, regardless of the origin, that massive amount of TGTX data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of TG Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of TG Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to TG Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive TG Therapeutics alpha.

TG Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 11337 shares by Power Sean A of TG Therapeutics at 30.294 subject to Rule 16b-3
01/03/2025
2
TG Therapeutics Entering 2025 With Increased Investor Expectations - Seeking Alpha
01/23/2025
3
All You Need to Know About TG Therapeutics Rating Upgrade to Buy
01/27/2025
4
Acquisition by Power Sean A of 87500 shares of TG Therapeutics subject to Rule 16b-3
01/29/2025
5
Acquisition by Weiss Michael S of 750000 shares of TG Therapeutics subject to Rule 16b-3
01/30/2025
6
Fluor Corp. Among the Best Infrastructure Stocks to Buy According to Hedge Funds
02/12/2025
7
Opaleye Management Inc. Adjusts Holdings in Ocular Therapeutix Inc.
02/14/2025
8
TG Therapeutics Announces Schedule of Data Presentations for BRI
02/18/2025
9
Novavax to Report Q4 Earnings Heres What You Can Expect
02/19/2025
10
Acquisition by Weiss Michael S of 100000 shares of TG Therapeutics at 10.13 subject to Rule 16b-3
02/21/2025
11
Institutional investors in TG Therapeutics, Inc. see US243m decrease in market cap last week, although long-term gains have benefitted them.
02/25/2025
12
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2024 Financial Results and Business Update
02/26/2025
13
TG Therapeutics Q4 2024 Earnings Preview
02/28/2025

Additional Tools for TGTX Stock Analysis

When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.